pembrolizumab,BXCL701
merck,BioXcel Therapeutics
['#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'pembro']
ph iia trial bxcl701 + pembro in small cell ne pca median # prior systemic therapy line=3 &amp; 62% w/ visceral mets orr 20%, median response duration: 6+ mo all 5 patients w/ orr had mss and/or low tmb (historically poor resp to pembro mono) gr 3+ aes: 47%
#gu23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @AUB_Lebanon and @MCG_Urology